Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric G Meissner

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Annals of Internal Medicine|June 16, 2025
Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness AnalysesAshish A Deshmukh, Haluk Damgacioglu, Keith Sigel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 28, 2016
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trialEric G Meissner, Mary McLaughlin, Lindsay Matthews, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Annals of Internal Medicine|June 16, 2025
Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness AnalysesAshish A Deshmukh, Haluk Damgacioglu, Keith Sigel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 28, 2016
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trialEric G Meissner, Mary McLaughlin, Lindsay Matthews, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 8